hemangioendothelioma/tyrosine

Nuoroda įrašoma į mainų sritį

StraipsniaiKlinikiniai tyrimaiPatentai

Pasirinkite rūšiavimo tipą

Puslapis 1 nuo 18 rezultatus

Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case Reports.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Sunitinib malate (Sutent(TM); Pfizer Inc., New York, N.Y., USA) is a small molecule kinase inhibitor with activity against a number of tyrosine kinase receptors, including vascular endothelial growth factor receptors, stem-cell factor receptor, and platelet-derived growth factor receptors alpha and

Effective Treatment of Pleural Epitheloid Hemangio-endothelioma with Pazopanib: A Case Report.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

A patient with a pleural epitheloid hemangio-endothelioma (EHE) who failed to respond to six cycles of initial chemotherapy with iphosphamide and epirubicine was treated with pazopanib in second-line. A significant subjective and objective metabolic response on (18)F-fluoro-deoxyglucose

Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Epithelioid hemangio-endothelioma (EHE) is a rare malignant tumor of vascular origin that electively metastasizes to lungs and liver. METHODS We report the case of a 51-year-old woman with metastatic and progressive EHE of the liver. She was successfully treated with daily administration

Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Epithelioid hemangioendothelioma (EHE) is a low-grade, malignant vascular tumor that most commonly presents within the liver. Patients with hepatic EHE are often candidates for liver transplantation as the disease is usually multifocal at diagnosis. Although these patients achieve excellent early

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Purpose: Pseudomyogenic hemangioendothelioma (PHE) is an extremely rare locally aggressive neoplasm with endothelial differentiation, which often presents with multiple lesions. These tumors have characteristic SERPINE1-FOSB fusions. We report a 17 years old patient with advanced unresectable PHE

Epithelioid hemangioendothelioma of the kidney treated with sunitinib.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Metastatic epithelioid hemangioendothelioma of the kidney is a rare malignant vascular tumor with a wide spectrum of behaviors. METHODS We present the case of a 53-year-old male patient with tumor metastases which developed after radical nephrectomy. We describe the immunohistochemistry

Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE This review highlights the current body of knowledge regarding the role of the vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in angiosarcoma, epithelioid hemangioendothelioma (EHE), and hemangiopericytoma/solitary fibrous tumor (HPC/SFT). Therapeutic agents that target

Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Recently, a novel monoclonal antibody to vascular endothelial growth factor receptor 3 (VEGFR-3), a tyrosine kinase receptor expressed almost exclusively by lymphatic endothelium in the adult, has been shown to react with a small number of cases of Kaposi's sarcoma (KS) and cutaneous lymphangiomas.

Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Pulmonary epithelioid hemangioendothelioma (P-EHE) is a rare tumor, with no established standard treatment. Overexpression of vascular endothelial growth factor receptor 2 (VEGFR-2) has been reported in some P-EHE patients. Apatinib, a new small molecule tyrosine kinase inhibitor that

18-F-FDG PET-CT in Monitoring of Chemotherapeutic Effect in a Case of Metastatic Hepatic Epithelioid Hemangioendothelioma.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Hepatic epithelioid hemangioendothelioma is a rare variant of mesenchymal tumor. Surgical resection or partial hepatectomy is the treatment of choice in the case of localized disease. However, in metastatic cases, chemotherapeutic drugs targeting the tyrosine kinase are being used. We hereby present

Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Vascular endothelial growth factor receptor 2 (VEGFR2) is a primary responder to vascular endothelial growth factor signal and thereby regulates endothelial migration and proliferation. This receptor is expressed in endothelial cells and in some vascular tumors, but many reports also detail its

Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The mouse is the most commonly used species for in vivo studies on angiogenesis related to tumor development. Yet, to the best of our knowledge, very few reports on the in vitro interaction of the angiogenic basic fibroblast growth factor (bFGF) with mouse endothelial cells are available. Three

Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Among the molecules important to angiogenesis and lymphangiogenesis is vascular endothelial growth factor receptor 3 (VEGFR-3), a member of the receptor tyrosine kinases of endothelial cells. This receptor is expressed consistently in normal lymphatics, lymphangiomas, and in Kaposi

KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

C-kit proto-oncogene product (KIT, CD117) is a tyrosine kinase growth factor receptor for stem cell factor. This receptor is important for the development and maintenance of hematopoietic stem cells, mast cells, germ cells, melanocytes, and interstitial cells of Cajal and is constitutively expressed

Vascular Anomalies: From a Clinicohistologic to a Genetic Framework.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Vascular anomalies currently are classified according to their clinical and histological characteristics. Recent advances in molecular genetics have enabled the identification of somatic mutations in most types of vascular anomalies. The purpose of this study was to collate information regarding the

Ankstesnis
1
2
Kitas

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais